Hitachi overcomes conservatism and brings MAST in
This article was originally published in Clinica
Japanese companies have a reputation for conservatism. Nonetheless, it is surprising that MAST Immunosystems was exhibiting at the AACC at the first time under its new name of Hitachi Chemical Diagnostics - even though the Japanese company had bought a 75% interest in MAST as long ago as 1996.
You may also be interested in...
Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.
Oncologic Drugs Advisory Committee votes 6-5 that ramucirumab’s benefit/risk profile is favorable in first-line lung cancer, but 13-2 that pivotal trial data do not support approval of Steba’s vascular-targeted, photodynamic therapy for low-risk prostate cancer.